---
title: "Lakewood-Amedex Biotherapeutics flags new press release available on Nu-3 resistance data"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293470541.md"
description: "Lakewood-Amedex Biotherapeutics released data on July 22, 2026, regarding its Phase 2-ready candidate Nu-3 for infected diabetic foot ulcers. The new resistance data indicates no induced resistance in serial-passage studies, supporting the drug's membrane-disruption mechanism and its potential in antimicrobial-resistance-focused development."
datetime: "2026-07-22T12:04:25.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293470541.md)
  - [en](https://longbridge.com/en/news/293470541.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293470541.md)
---

# Lakewood-Amedex Biotherapeutics flags new press release available on Nu-3 resistance data

-   Lakewood-Amedex published a July 22, 2026 release highlighting new resistance data for Nu-3, its Phase 2-ready infected diabetic foot ulcer candidate. \* Nu-3 showed no induced resistance in a serial-passage study, supporting its membrane-disruption mechanism and positioning in antimicrobial-resistance-focused development. \* Release: here Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lakewood-Amedex Biotherapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY09340) on July 22, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [LABT.US](https://longbridge.com/en/quote/LABT.US.md)

## Related News & Research

- [Lakewood-Amedex Biotherapeutics makes Investor Deck public, Nu-3 Phase 2a planned with IND open](https://longbridge.com/en/news/292813307.md)
- [08:02 ETLakewood-Amedex Expands Global IP Portfolio for Lead Candidate, Nu-3, Targeting Infected Diabetic Foot Ulcers](https://longbridge.com/en/news/287767752.md)
- [Artisan Partners tops 10% stake in Sodexo, filing shows](https://longbridge.com/en/news/293332028.md)
- [Celldex Reports Results From Phase 2 Study Of Barzolvolimab In Prurigo Nodularis](https://longbridge.com/en/news/293391923.md)
- [Sodexo liquidity contract holds 77,960 shares, EUR 11.23 million as of June 30, 2026](https://longbridge.com/en/news/293365662.md)